Arkstone Partners with Neslab to Revolutionize Healthcare in Peru
BOCA RATON, Fla., Feb. 6, 2025 /PRNewswire/ -- Arkstone Medical Solutions is proud to announce a groundbreaking partnership with Neslab, a...
Antimicrobial
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
SALT LAKE CITY, Jan. 30, 2025 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life,...
Qualigen to participate in next funding round for NanoSynex
Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
Thursday, January 23rd, 2025 at 4:15pm Eastern TimeWINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE;...
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to...
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business,...
BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™...
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc....
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...
Teleflex awarded Short Term Central Venous Catheters contract from Vizient
Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a...
Chungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic Detection
DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes,...
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases
Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec....
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
Milestone demonstrates the growing customer adoption of the Company’s proprietary technologyLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems,...
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing...